<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014364</url>
  </required_header>
  <id_info>
    <org_study_id>PCR09006</org_study_id>
    <nct_id>NCT01014364</nct_id>
  </id_info>
  <brief_title>Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu</brief_title>
  <acronym>CORTIFLU</acronym>
  <official_title>Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Versailles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Versailles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is
      rapidly progressing worldwide and a substantial number of patients get severe H1N1 related
      pneumonia that requires mechanical ventilation and admission to the intensive care unit. The
      acute respiratory distress syndrome is associated with a substantial mortality and morbidity
      partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are
      trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these
      drugs may cause super infection or metabolic disorders. Thus, there is a need for a
      randomized double blind, placebo controlled trial to define the benefit to risk ratio of
      corticosteroids in this patient.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the H1N1 pandemic is now over, and fewer cases than expected were observed
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in hospital all cause morality</measure>
    <time_frame>hospital discharge up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day all cause mortality</measure>
    <time_frame>90 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month all cause mortality</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation free days</measure>
    <time_frame>hospital discharge up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intensive care unit free days</measure>
    <time_frame>hospital discharge up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with secondary infections</measure>
    <time_frame>hospital discharge up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients who require ECMO</measure>
    <time_frame>hospital discharge up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function and health status</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pneumonia, Viral</condition>
  <condition>Influenza in Humans</condition>
  <arm_group>
    <arm_group_label>Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isotonic saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone</intervention_name>
    <description>50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week</description>
    <arm_group_label>Corticosteroids</arm_group_label>
    <other_name>hydrocortisone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 15 years old

          -  admitted to intensive care unit

          -  proven or strong suspicion of H1N1 Influenza infection

          -  diffuse pneumonia (for less than 96 hours)

          -  need for non invasive or invasive mechanical ventilation

        Exclusion Criteria:

          -  pregnancy

          -  an age of 15 or less

          -  rapidly fatal underlying disease with a life expectancy of one month or less

          -  more than 3 organ dysfunction upon admission

          -  previous treatment with corticosteroids (ie prednisone 30 mg per day or more, or
             equivalent, for at least one month)

          -  formal indication for corticosteroids (eg Addison disease, status asthmaticus)

          -  already on corticosteroids for 2 days or more in the management of the current episode

          -  acute lung injury not related to viral pneumonia

          -  presence of H1N1 related acute myocarditis or encephalitis

          -  receiving antiviral treatment for more than 5 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali Annane, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AP--HP and University of Versailles SQY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Brun Buisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP and Paris XII University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Mayaud</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP and University of Paris VII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Régnier</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP and Paris VII University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Perronne</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP and University of Versailles SQY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Raymond Poincaré hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Annane D, Antona M, Lehmann B, Kedzia C, Chevret S; CORTIFLU Investigators; CRICs; AZUREA; REVA/SRLF networks. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. Intensive Care Med. 2012 Jan;38(1):29-39. doi: 10.1007/s00134-011-2409-8. Epub 2011 Nov 26.</citation>
    <PMID>22120766</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Versailles</investigator_affiliation>
    <investigator_full_name>Djillali Annane</investigator_full_name>
    <investigator_title>Dean of the health Science Centre</investigator_title>
  </responsible_party>
  <keyword>Acute lung injury</keyword>
  <keyword>Acute respiratory distress syndrome</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

